Aug 2026· Biomaterials Advances· Vol 189, pp.
215113
· 0 citations· 48 references
Medicine
TL;DR
The NCRPF nanotherapeutic system provides a powerful new paradigm with high translational potential for the complete eradication of breast cancer, and both in vitro and in vivo results confirm that this combined strategy achieves complete tumor eradication with favorable biosafety.
Abstract
The antioxidant defense barrier in the tumor microenvironment, particularly glutathione (GSH), considerably restricts the therapeutic efficacy of chemodynamic therapy (CDT). Moreover, CDT generally exhibits relatively mild therapeutic efficacy owing to its intrinsic reaction kinetics, making it difficult to achieve complete tumor eradication within a short time. To address these issues, we construct a functionalized nanotherapeutic platform, Nb2CTx@Ru-PEG2000-FA (NCRPF), for tumor photothermal ablation and enhanced CDT resulting from GSH depletion. NCRPF possesses three key advantages: 1. Efficient near-infrared II photothermal conversion (η = 42.08%), raising the tumor temperature above 45 °C within 90 s for rapid ablation; 2. Dual peroxidase-like and glutathione peroxidase-like activities, simultaneously depleting GSH and generating a burst of ·OH to eliminate residual tumors; 3. Targeted tumor accumulation with 2.9-fold higher efficiency than passive diffusion. Both in vitro and in vivo results confirm that this combined strategy achieves complete tumor eradication with favorable biosafety. Collectively, the NCRPF nanotherapeutic system provides a powerful new paradigm with high translational potential for the complete eradication of breast cancer.
This review constructs a refined mechanistic framework to elaborate the complementary mechanisms of PDT and PTT toward CDT in terms of reaction kinetics modulation, endogenous substrate replenishment, and tumor antioxidant defense inhibition, and the key bottlenecks hindering clinical translation.
Yuxuan Ma, Jie Gong, Zixuan Wu et al.· International Journal of Nan...· 0 citations
Cerium molybdate-doped polyaniline nanoparticles are developed to enable a synergistic combination of photothermal therapy (PTT) and CDT, thereby triggering immunogenic cell death (ICD) and enhancing antitumor immunity and presenting a robust nanoplatform integrating chemodynamic and photothermal therapies for potent cancer immunotherapy.
Yulin Kuang, Cheng Lu, Bolan Yu et al.· Bioactive Materials· 0 citations
Introduction Photothermal therapy (PTT) faces limitations due to tumor microenvironment (TME) heterogeneity and single-modality constraints, including hypoxia, redox imbalance, and uneven heat distribution, which compromise therapeutic durability. Integrating nanozyme catalysis with PTT presents a promising strategy to amplify oxidative stress, yet achieving a balance among catalytic efficiency, photothermal performance, biocompatibility, and stability remains challenging. Methods Herein, we developed an epigallocatechin gallate (EGCG)-modified palladium-based nanozyme (EGCG-PdZyme) for the precision treatment of esophageal cancer. This multifunctional platform was engineered to integrate catalase-like oxygen generation, peroxidase-like reactive oxygen species (ROS) production, and near-infrared photothermal conversion capabilities. Results While EGCG modification slightly attenuated the intrinsic catalytic activity and peak photothermal temperature, it established an optimized thermo-catalytic synergy. Sustained mild hyperthermia amplified oxidative stress, effectively offsetting the reduced catalytic output and minimizing thermal damage to peritumoral tissues. Mechanistically, persistent photothermal heating boosted enzymatic ROS generation within the TME, initiating a self-amplifying therapeutic cascade. Furthermore, EGCG functionalization significantly enhanced colloidal stability and biosafety, enabling effective tumor ablation with negligible systemic toxicity. Discussion This study demonstrates a paradigm shift from maximizing isolated parameters toward achieving a dynamic equilibrium between catalytic functionality and biological compatibility. By integrating TME modulation with controlled photothermal amplification, the EGCG-PdZyme platform offers a viable strategy for clinically translatable precision oncotherapy.
Yuhang Shang, Yujie Zhao, Qi Li et al.· Frontiers in Pharmacology· 0 citations
This work provides an effective nanoplatform integrating tumor targeting, oxygen self-supply, and dual-mode GSH depletion to potentiate synergistic PTT/PDT for melanoma therapy.
Photodynamic therapy (PDT) efficacy is severely compromised by tumor hypoxia and the scarcity of efficient type-I photosensitizers, necessitating multimodal therapeutic strategies. Herein, we report a porphyrin-Cu (II) covalent organic framework (TBCOF) with intrinsic bifunctional photodynamic and chemodynamic activities. Sequential DOX encapsulation and hyaluronic acid (HA) surface functionalization afford HA-TBCOF@DOX, a tumor-targeted nanoplatform integrating four synergistic therapeutic modalities. Under 660 nm laser irradiation, the nanoplatform generates ROS signatures consistent with both type-I and type-II pathways for PDT, while the intrinsic Cu2+ centers are proposed to catalyze a Fenton-like reaction consistent with •OH generation for CDT. Concurrently, observations of O2 evolution suggest catalase-like activity that may decompose endogenous H2O2 into O2, alleviating hypoxia and potentiating oxygen-dependent PDT. Efficient photothermal conversion and pH-triggered DOX release contribute to photothermal and chemotherapeutic effects, respectively, while HA-mediated CD44 targeting enhances cellular uptake and therapeutic specificity. In vitro and in vivo studies demonstrate that laser-activated HA-TBCOF@DOX effectively suppresses tumor growth, induces apoptosis, and exhibits no apparent systemic toxicity under the tested experimental conditions. This work establishes a multifunctional COF-based nanoplatform that addresses PDT limitations observed in this study by integrating intrinsic PDT and CDT, providing a robust strategy for synergistic multimodal cancer therapy.
Yongjie Mo, Jie Hou, Hong-Li Li et al.· Materials Today Bio· 0 citations
By integrating receptor-mediated targeting, redox homeostasis disruption, and chemosensitization, MnO2@Man/DOX offers a promising metabolism-oriented strategy for treating refractory TNBC.
Guanghui Mei, Hanwen Wang, Xinhua Lin et al.· Nanomedicine: Nanotechnology...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.
